Welcome to our dedicated page for ARCH BIOPARTNERS ORD news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on ARCH BIOPARTNERS ORD stock.
Arch Biopartners Inc. (OTCQB: ACHFF) is a clinical-stage biopharmaceutical company focused on developing new therapies for the prevention of inflammation and acute organ injury. Their primary area of research targets the dipeptidase-1 (DPEP-1) pathway, which plays a crucial role in inflammation in the lungs, kidneys, and liver.
The Company's leading drug candidate, LSALT peptide, aims to treat and prevent cardiac surgery-associated acute kidney injury (CS-AKI), a significant complication following cardiac surgeries, particularly those involving cardiopulmonary bypass. LSALT peptide has received approval for Phase II trials in several countries, including Turkey and Canada. Arch Biopartners is also exploring other potential applications for LSALT peptide, such as treating inflammation caused by SARS-CoV-2 virus infection.
In their latest developments, Arch Biopartners announced several milestones, including:
- Approval from the Turkish Ministry of Health and Health Canada for Phase II trials targeting CS-AKI.
- Patient recruitment and dosing have begun in Turkey, with participation from multiple hospital sites.
- Collaboration with major research institutions like the University of Calgary's Cumming School of Medicine and the University Health Network in Toronto.
- Publication of Phase II trial results for LSALT Peptide in the British Medical Journal Open detailing its efficacy in reducing inflammation.
Arch Biopartners operates with a robust intellectual property portfolio and actively collaborates with leading researchers and institutions to advance their drug candidates. The Company has 62,755,633 common shares outstanding and provides detailed investor information and scientific publications on their website.
Arch Biopartners has appointed Dr. David Luke as a Strategic Advisor for clinical trial development. Dr. Luke brings over 20 years of experience from Pfizer and other firms, where he oversaw various human trials. His involvement will focus on advancing LSALT peptide, which targets inflammation related to acute kidney injury, following its prior use in COVID-19 trials. Arch Biopartners is dedicated to developing therapies addressing organ inflammation through innovative technologies. The company currently has 62,330,302 shares outstanding.
Arch Biopartners announced Health Canada's approval for the inclusion of its drug candidate LSALT Peptide in the CATCO clinical trial, aimed at treating organ inflammation in COVID-19 patients. The amendment allows LSALT to be used in a new dosing arm, with trials expected to begin after local approvals. The CATCO study involves up to 55 hospitals across Canada and targets approximately 350 patients suffering from complications due to COVID-19. LSALT's focus is on reducing organ inflammation irrespective of COVID-19 variants.
Arch Biopartners announced a publication in Science Advances detailing the mechanism of action of dipeptidase-1 (DPEP-1) in acute kidney injury (AKI). The study, led by Dr. Daniel Muruve, highlights how DPEP-1 regulates inflammation in the kidneys post-injury. It also confirms the protective effects of two DPEP-1 inhibitors, LSALT peptide and cilastatin, during ischemia-reperfusion injury. Arch plans to pursue a phase II trial targeting cardiac surgery-related AKI, providing a significant step forward for developing therapies in this area.
Arch Biopartners Inc. announced that the Research Ethics Board at Sunnybrook Research Institute approved an amendment to the CATCO trial protocol, allowing the inclusion of their lead drug candidate, LSALT Peptide (LSALT), to target acute organ inflammation related to COVID-19. The company will supply LSALT vials for dosing approximately 350 patients. CATCO, a multi-centre study, aims to find new treatments for COVID-19 complications. Arch seeks Health Canada approval before commencing the new dosing arm.
Arch Biopartners has announced that its lead drug candidate, LSALT Peptide, will enter the Canadian Treatments for COVID-19 (CATCO) trial. This clinical study will involve 320 patients across 65 hospitals in Canada and is aligned with the WHO’s SOLIDARITY trial. The decision follows positive Phase II trial results, indicating more ventilation-free days for LSALT patients compared to placebo. The trial will assess LSALT’s efficacy in treating acute organ inflammation in COVID-19 patients, supported by the Sunnybrook Research Institute and Health Canada approvals.
Arch Biopartners has announced ongoing analysis of its Phase II trial results for the LSALT peptide (Metablok), aimed at preventing organ inflammation due to COVID-19. The trial involved multiple clinical sites and evaluated the drug's effectiveness against ARDS and AKI. Recruitment was completed in May, with data reconciliation finalized in June, allowing analysis to start in July. The company plans to disclose results after peer review and aims to use the findings to inform a future Phase III program.
Arch's pipeline includes LSALT peptide as a DPEP-1 inhibitor, with patent protection for cilastatin to prevent acute kidney injury.
Arch Biopartners Inc. announced the awarding of a CIHR Team Grant worth $750,000 to its scientists for research on the LSALT peptide (Metablok) to prevent inflammation in chronic kidney and lung diseases. This study will advance understanding of DPEP-1, an adhesion receptor for neutrophils, and its role in organ inflammation during acute illnesses like AKI and ARDS. The funds will aid pre-clinical studies and optimize clinical trial designs targeting DPEP-1, alongside supporting ongoing drug development within Arch's portfolio.
Arch Biopartners Inc. has filed a new provisional patent application to protect antibody drug candidates targeting inflammation mediated by dipeptidase-1 (DPEP-1) in the lungs, liver, and kidneys. This filing enhances its patent portfolio and introduces a novel class of therapeutics alongside existing peptide candidates. The company also concludes patient recruitment for its Phase II trial of LSALT peptide (Metablok), which aims to prevent organ inflammation in COVID-19 patients. The trial's results will inform the design of future Phase III studies.
Arch Biopartners Inc. (ACHFF) has completed enrollment for its Phase II trial of Metablok (LSALT Peptide), aimed at treating acute lung and kidney injuries caused by inflammation in severe COVID-19 cases. A total of 65 patients participated, with results expected in July 2021. The trial is designed to assess Metablok's efficacy in preventing organ inflammation that can lead to severe complications in COVID-19 patients. Positive outcomes may inform a Phase III program with a larger patient cohort.
Arch Biopartners has entered an exclusive global license agreement with Telara Pharma to develop cilastatin, a small-molecule drug aimed at preventing acute kidney injury (AKI). This collaboration unifies existing patents and supports a new Phase II trial targeting AKI, a condition affecting 10-15% of hospitalized patients, with a market valued over $20 billion. Cilastatin, previously used in combination with imipenem, inhibits dipeptidase-1 (DPEP-1), an adhesion receptor linked to inflammation. Arch's Metablok is also in trials addressing similar pathways.
FAQ
What is the current stock price of ARCH BIOPARTNERS ORD (ACHFF)?
What is the market cap of ARCH BIOPARTNERS ORD (ACHFF)?
What is Arch Biopartners Inc. focused on?
What is LSALT peptide?
What recent approvals has Arch Biopartners received for LSALT peptide?
Which hospitals are participating in the Phase II trials for LSALT peptide?
What are some key findings from the Phase II trial for LSALT peptide?
What is cardiac surgery-associated acute kidney injury (CS-AKI)?
How does LSALT peptide work?
Has Arch Biopartners published any scientific papers?
How many shares does Arch Biopartners have outstanding?
Where can I find more information about Arch Biopartners?
